Zeenat Parween, Correspondent, India Pharma Outlook
Walk into any urban clinic in India today and you will hear one name migrating from endocrinology journals to dinner-table conversation: semaglutide.
Since the drug's Indian patent expired on March 20, 2026, generics from Dr. Reddy's, Sun Pharma, and Natco have entered the market at 50–80 percent below branded pricing — Rs 900–2,000 per month versus Wegovy's earlier Rs 16,400.
But most patients still have only a hazy picture of what semaglutide actually does. That picture matters enormously.
Every time you eat, cells in your small intestine release glucagon-like peptide-1 (GLP-1) — a hormone that signals the pancreas to release insulin, slows stomach emptying, and tells the brain calories have arrived. The problem: natural GLP-1 lasts roughly two minutes before an enzyme destroys it. Novo Nordisk's chemists attached a fatty acid chain and swapped a single amino acid to create semaglutide, extending the half-life to ~165 hours. One weekly injection. That is the core engineering insight behind the GLP-1 receptor agonist class.
The most consistent patient report is not measured in kilograms — it is the quiet that descends over the near-constant mental chatter about food. GLP-1 receptors sit in the nucleus accumbens, the brain's reward hub. Semaglutide activates them, reducing the motivational pull of food. Patients don't feel deprived; food becomes less interesting. Neuroimaging studies show reduced activity in the insula and orbitofrontal cortex — the craving centres — when participants on semaglutide view pictures of food. This is fundamentally different from older stimulant-based appetite suppressants.
Semaglutide also activates GLP-1 receptors along the vagus nerve, slowing gastric emptying — a meal that clears the stomach in 90 minutes normally can take three to four hours. That prolonged distension keeps 'still full' signals running to the brain. It also explains the most common side effect: nausea, which peaks during dose escalation and typically resolves within 4–8 weeks at a stable dose.
Also Read: Oral GLP-1 Drugs: Expanding Patient Access in Obesity and Diabetes Care
Unlike older diabetes drugs, semaglutide triggers insulin release only when blood glucose is elevated — the glucose-dependent mechanism that keeps hypoglycaemia risk low. It also suppresses glucagon, preventing the blood-sugar spikes and reactive crashes that drive mid-afternoon hunger. The cumulative effect is a recalibration of the body's defended weight set-point — not brute-force willpower, but a quieter biological reset.
Both are semaglutide — same molecule, same manufacturer (Novo Nordisk). Ozempic is approved for type 2 diabetes at up to 2 mg weekly. Wegovy is approved for chronic weight management at 2.4 mg weekly, reached via a 16-week dose escalation starting at 0.25 mg. The higher dose is not arbitrary — the dose-response curve for weight loss is steep. Using Ozempic off-label for obesity delivers some benefit, but not the full obesity-indicated effect.
The STEP programme generated the most comprehensive obesity drug dataset in decades. STEP 1 (NEJM, 2021) enrolled adults with BMI ≥30 on semaglutide 2.4 mg for 68 weeks alongside lifestyle counselling:
14.9 percent mean body weight reduction (vs. 2.4 percent on placebo) — STEP 1
69–79 percent of participants lost ≥10 percent body weight across STEP 1, 3, 4, 8
15.2 percent weight loss maintained at 104 weeks — STEP 5 two-year data
20.7 percent weight loss with investigational 7.2 mg dose — STEP UP (2025 ADA)
Approved for adults with BMI ≥30 (obesity), or ≥27 (overweight) with at least one weight-related complication — type 2 diabetes, hypertension, dyslipidaemia, or sleep apnoea. In March 2024, the FDA added a cardiovascular indication: the SELECT trial (17,500 participants) showed a 20 percent relative reduction in major cardiovascular events in patients with pre-existing disease. Semaglutide is now as much a cardiovascular drug as a weight-loss drug.
"Semaglutide presents a timely opportunity to provide an effective solution for the growing obesity and diabetes burden in India," said Vikas Gupta, CEO of Alkem Laboratories.
Two conditions generating significant clinical interest in India: PCOS affects an estimated 20–22 percent of Indian women of reproductive age. Early data show semaglutide improves insulin sensitivity, reduces androgens, and helps restore menstrual regularity. And for metabolic dysfunction-associated steatotic liver disease (MASLD) — which affects ~40 percent of Indian adults with type 2 diabetes — phase 2 data demonstrate reductions in liver fat and histological improvement. Phase 3 trials are ongoing.
Semaglutide's side effect profile is well-characterised and, for most patients, manageable. The key is understanding that the gastrointestinal complaints are largely dose-dependent and time-limited.
Nausea — the most common complaint, reported in approximately 44 percent of semaglutide participants vs. 16 percent on placebo in STEP 1. Peaks during dose escalation and typically resolves within 4–8 weeks of reaching a stable dose. Eating smaller portions, avoiding high-fat or spicy food, and not lying down immediately after eating significantly reduce severity.
Vomiting — occurs in around 24 percent of patients, again most pronounced during escalation. Often pairs with nausea. If vomiting is persistent beyond the initial weeks, the dose escalation schedule should be slowed.
Diarrhoea — reported in approximately 30 percent of participants. Usually mild and self-limiting. Staying hydrated is the primary management strategy.
Constipation — counterintuitively, slowed gastric emptying can also cause constipation, particularly as the drug's effects cascade down the gastrointestinal tract. Increased fibre and fluid intake help.
Gallbladder disease — one of the more serious but less discussed risks. Gallbladder-related disorders, mostly gallstones (cholelithiasis), were reported in 2.6 percent of semaglutide participants vs. 1.2 percent on placebo in STEP 1. Rapid weight loss of any cause increases gallstone risk, and semaglutide is no exception. Patients with a history of gallstones should be monitored.
"The entry of generic semaglutide will unlock significant latent demand, providing a strong boost to an already expanding market," according to Neeraj Sharma of OneSource Specialty Pharma.
Semaglutide carries the FDA's most serious caution — a black box warning — for thyroid C-cell tumours (medullary thyroid carcinoma). This originates from rodent studies at supratherapeutic doses. Human thyroid C-cells express GLP-1 receptors at far lower densities; decades of GLP-1 agonist use have not produced a confirmed human MTC signal. Nevertheless, semaglutide is contraindicated in patients with a personal or family history of MTC or MEN 2 syndrome.
The STEP 1 extension answered this bluntly: patients who lost a mean of 17.3 percent regained 11.6 percentage points within 52 weeks of stopping — a net maintained loss of just 5.6 percent. The weight comes back because obesity is a chronic condition; the biological drivers of weight gain reassert themselves when pharmacological suppression ends. The clinical community is increasingly modelling semaglutide like a statin: long-term therapy for a chronic condition, not a finite course.
During the global shortage (2022–2024), unregulated compounding pharmacies sold semaglutide-containing injections — many with inaccurate doses or contamination risks. In India today, the affordable alternatives are CDSCO-approved generics from regulated manufacturers, not compounded products. Sun Pharma's Noveltrast and Sematrinity, Natco's vial formulation, and Dr. Reddy's generic are manufactured to regulatory standards with full pharmacovigilance obligations. Unregulated online products remain a genuine patient safety risk.
Inject subcutaneously once a week — abdomen, front thigh, or upper arm — rotating sites each time. Escalation: 0.25 mg (weeks 1–4) → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg maintenance, four weeks at each step. Store pens refrigerated (2–8°C); once opened, they are stable at room temperature below 30°C for 28 days. Missed a dose? Inject within five days of the scheduled day. Beyond five days, skip it and resume the regular weekly schedule.
Rybelsus (3 mg, 7 mg, 14 mg tablets) is approved for type 2 diabetes — not obesity — and its weight-loss effect at 14 mg is meaningfully less than injectable 2.4 mg. The reason: oral bioavailability is only 0.4–1 percent, versus ~89 percent for the injection. It must be taken on an empty stomach with ≤120 mL of plain water, 30 minutes before any food or other medication. Non-adherence cuts absorption by up to 50 percent. An investigational oral 50 mg formulation (OASIS programme) is closing the efficacy gap and may expand options as global approvals progress.
SURMOUNT-5 (NEJM, May 2025) delivered the verdict: tirzepatide (a dual GLP-1/GIP agonist) produced −20.2 percent weight loss versus semaglutide's −13.7 percent at 72 weeks — a clear win on scale. One in three tirzepatide participants lost ≥25 percent of starting body weight. However, semaglutide's cardiovascular trial (SELECT, 17,500 patients, 20 percent reduction in major events) remains the more mature evidence base. For patients whose primary driver is metabolic risk rather than weight alone, semaglutide's cardiovascular data still matter.
Yes — roughly 15–25 percent of weight lost is lean mass, similar to dietary restriction alone but significant at 15–20 percent total weight loss. Lower lean mass reduces resting metabolic rate, accelerating regain after stopping. The three-part counter-strategy: progressive resistance training (not just walking), dietary protein at 1.2–1.6 g/kg/day, and a conservative escalation schedule to avoid rapid early loss that disproportionately draws on muscle.
The IDF's 2025 Diabetes Atlas estimates 89.8 million Indian adults were living with diabetes — second only to China. GLP-1 drug sales in India grew 178 percent year-on-year in February 2026 (Pharmarack), before generic competition had fully launched. Dr. Rajiv Kovil, a Mumbai diabetologist, estimated that 50 percent of his patients could clinically benefit from GLP-1 therapy — but only 5 percent were accessing it before generics arrived.
"Our goal is to democratise access to GLP-1 drugs worldwide. We are targeting annual sales of 12 million semaglutide pens in the first year of launch across all markets, including India," said Deepak Sapra, CEO of Pharmaceutical Services and API, Dr. Reddy's Laboratories
"These drugs are not magic bullets. They work best combined with sustained lifestyle changes and regular monitoring. The challenge is not starting patients on semaglutide — it is ensuring they stay on treatment safely over the long term," said Dr. Rajiv Kovil, Diabetologist, Mumbai
With patent expiry, the landscape has changed. CDSCO-approved generics from Dr. Reddy's, Sun Pharma (Noveltrast/Sematrinity), Natco, Zydus, and Alkem are now legally available on prescription. Monthly costs range from Rs 900–Rs 2,000 — a fraction of pre-generic branded pricing. The rule is simple: get it prescribed by a qualified physician, dispensed by a licensed pharmacy, and sourced from a manufacturer with CDSCO approval. Anything sold through unverified online channels without a prescription remains both legally and clinically risky.
Semaglutide is not a miracle. It is a well-engineered molecule that extends a hormone the gut already makes, works on hunger, reward circuitry, gastric emptying, and glucose simultaneously — and produces weight loss that is clinically meaningful, well-documented, and sustained for as long as the drug is taken. The weight returns when it stops. Some muscle is lost alongside fat. The side effects during escalation are real but manageable. And for the tens of millions of Indians living with metabolic disease, the patent expiry means this therapy is no longer a luxury. Whether it becomes a genuine public health tool depends on the prescribing infrastructure that surrounds it — not the molecule itself.
Q1. If semaglutide works so well, why does all the weight come back after stopping it?
Because semaglutide doesn't fix the underlying biology of obesity — it overrides it, temporarily. While you're on it, the body behaves as though its weight set-point has been lowered. Stop the drug, and ghrelin (the hunger hormone) rises, resting metabolic rate drops, and the body pushes back toward its original defended weight — the same way blood pressure returns when you stop antihypertensives. The STEP 1 withdrawal data put a number on it: patients who lost 17.3% regained 11.6 percentage points within 52 weeks of stopping. This is not a drug failure; it's the nature of obesity as a chronic condition. Semaglutide, for most patients, needs to be thought of as long-term therapy — not a course you complete and walk away from.
Q2. Is the nausea unavoidable, or is there a way to start without feeling sick every day?
Nausea is common but not inevitable at its worst — and severity is almost entirely within the patient's control. The drug is designed to start at 0.25 mg weekly for four weeks before any dose increase, precisely because the stomach needs time to adjust. Rushing this schedule is the single most reliable way to guarantee severe nausea and early dropout. Beyond the schedule, three adjustments make a significant difference: eating smaller portions, avoiding high-fat or spicy food during initial weeks, and not lying down for at least an hour after eating. For most patients who follow these steps, nausea peaks in weeks two to four of each dose step and then diminishes substantially.
Q3. Now that generic semaglutide is available in India, how do I know if what I'm buying is safe?
The distinction that matters most is regulatory status, not price. Following patent expiry, Dr. Reddy's, Sun Pharma (Noveltrast/Sematrinity), Natco, Zydus, and Alkem received CDSCO approval — these are manufactured to full pharmaceutical standards, carry pharmacovigilance obligations, and are dispensed on prescription through licensed pharmacies. What's unsafe is the parallel category of unlicensed products sold through unverified online platforms, often without requiring a prescription. These may carry incorrect doses, the wrong salt form, or contamination. The checklist: get a prescription from a qualified physician, fill it at a licensed pharmacy, verify the manufacturer's name against CDSCO-approved brands, and check for batch number, manufacturing date, and cold-chain instructions on the label. If any of those are missing — don't use it.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")